Articles related to PAIN MANAGEMENT

The primary end point was the area under the curve (AUC) of the daily worst bone pain score (assessed using the “worst pain” question from the Brief Pain Inventory, a 0 to 10 numerical rating scale [NRS]) for 5 consecutive days in the first chemotherapy cycle.

The FDA notice added that a letter was sent out about the recall. However, it did not include a press release or other specific details.

“It’s like a recipe—if you’re missing one ingredient, you may not obtain the same result.” — Pascal-André Vendittoli, MD, Université de Montréal

“Endometriosis pain can be incredibly burdensome for women and girls, and we know that on top of that pain, many patients experience understandable frustration due to delays in care.” – ACOG President Steven J. Fleischman, MD

The objective of the study was to characterize the real-world safety profile of TMS devices based on MAUDE-reported AEs, including symptom patterns, manufacturer-level variations, device issues, and reporting delays.

“The key word is association. This study does not establish causality. For absolute, catastrophic harm to an appropriately selected, monitored pain patient, the risk is small.” – Sean Mackey, MD, PhD, Chief of the Division of Stanford Pain Medicine